Sonnet BioTherapeuticsSONN
SONN
About: Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Employees: 13
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
66% more capital invested
Capital invested by funds: $130K [Q4 2024] → $216K (+$85.9K) [Q1 2025]
2.29% more ownership
Funds ownership: 2.96% [Q4 2024] → 5.25% (+2.29%) [Q1 2025]
11% less funds holding
Funds holding: 9 [Q4 2024] → 8 (-1) [Q1 2025]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for SONN.
Financial journalist opinion
Based on 5 articles about SONN published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Sonnet BioTherapeutics, Inc. (NASDAQ: SONN ) related to its merger with Rorschach I LLC. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company. Is it a fair deal?
Positive
Benzinga
2 weeks ago
Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?
Sonnet BioTherapeutics Inc. SONN stock surged Monday amid high trading volume following news of a transformative business combination with Rorschach I, backed by Atlas Merchant Capital and Paradigm.
Positive
Finbold
2 weeks ago
This stock rockets 260% after $900 million mega crypto deal
Shares of Sonnet BioTherapeutics (NASDAQ: SONN) soared in pre-market trading on Monday after the company announced a $888 million business combination to pivot into the cryptocurrency sector.
Neutral
Business Wire
2 weeks ago
SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN) and Rorschach I LLC is fair to Sonnet shareholders. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company. Halper Sadeh encourages Sonnet shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sa.
Neutral
GlobeNewsWire
2 weeks ago
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury
Neutral
GlobeNewsWire
2 months ago
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6 th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA.
Neutral
GlobeNewsWire
3 months ago
Sonnet Releases Virtual Investor "What This Means" Segment
- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010
Neutral
GlobeNewsWire
3 months ago
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ® )
Neutral
GlobeNewsWire
3 months ago
Sonnet Announces Release of Corporate Update Video
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a corporate update video. Access the video here.
Neutral
GlobeNewsWire
3 months ago
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of Directors has unanimously approved the appointment of current board member Raghu Rao, as Interim Chief Executive Officer of the Company, and the promotion of Stephen McAndrew, Ph.D., the Company's current Chief Business Officer, to President and Chief Business Officer of the Company. The Board intends to launch a CEO search.
Charts implemented using Lightweight Charts™